Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Libidus warning

This article was originally published in The Tan Sheet

Executive Summary

Using the natural health product Libidus, which contains vardenafil, the same active ingredient contained in GlaxoSmithKiline's/Schering-Plough's Levitra, could pose health risks, especially for people with heart problems, taking heart medications or at risk for stroke, Health Canada announces. Libidus, which is manufactured in Malaysia by Bio-Gulf, contains a modified form of vardenafil, but the substance is not declared on product packages, the Canadian health agency says. Winnipeg, Manitoba-based distributor NorthRegentRX has been contacted and is recalling the product from Canadian markets, the agency says. Results of an FDA survey from earlier this year identified Libidus, and six other supplements as illegal because they contain undeclared non-dietary chemicals similar or equivalent to sildenafil or vardenafil (1"The Tan Sheet" July 17, 2006, p. 4). Products containing vardenafil should not be used by people taking nitrate medication because combining the products could result in dangerously low blood pressure...

You may also be interested in...



FDA Survey Of ED Supplements Shows Contamination With Viagra, Levitra

A "first-of-its-kind" FDA survey of 17 dietary supplements marketed to treat erectile dysfunction revealed that seven of the products are actually illegal drugs due to adulteration with active ingredients used in Rx ED treatments, the agency states in a July 12 release

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel